# SNDL

Type: Company (SNDL)

Source: GetYourBrief — https://getyourbrief.com/entity/sndl
Canonical HTML page: https://getyourbrief.com/entity/sndl

## Recent coverage (3 stories, network-wide)

### Novavax Cut to Sell by Wall Street Zen as Stock Trades at $7.41
2026-08-04 12:11:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
Full story: https://gethealthbrief.com/story/novavax-sell-downgrade-wall-street-zen-health

### Wall Street Zen Slaps Sell Ratings on CME, Novavax, and SNDL – 3 Stocks to Watch
2026-08-04 12:11:28 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement.
Full story: https://getfinancebrief.com/story/wall-street-zen-downgrades-cme-nvax-sndl-finance

### Biotech Sell-Off: Novavax Downgraded to Sell Despite Revenue Beat
2026-08-04 12:11:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Full story: https://getbiobrief.com/story/novavax-sell-downgrade-biotech-pharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.